After semaglutide stops: what withdrawal studies actually show

Questions about stopping belong near the beginning of a treatment conversation. Cost, side effects, changing goals or access can all make continuity important to discuss. Research helps describe what happened to groups after semaglutide was withdrawn, but it does not provide a universal stopping schedule. Two often-cited studies used different designs and should be read separately.

STEP 4 tested continuation after a run-in

In STEP 4, participants first received semaglutide during a 20-week run-in. Those reaching the randomized phase either continued weekly treatment or changed to placebo, with lifestyle intervention in both groups. From week 20 to week 68, mean weight changed by −7.9% with continuation and +6.9% after the switch. These numbers describe the period after randomization, not total change from the first day.

The design provides a controlled comparison of continued treatment and withdrawal among people who reached that phase. It does not describe every person who initially considered or started semaglutide. The run-in and its eligibility requirements matter. When someone quotes the outcome, ask which people and which starting point the percentage represents.

The STEP 1 extension followed a subset off treatment

The STEP 1 extension followed 327 participants after the main trial ended. Study treatment and the lifestyle intervention ended at week 68; follow-up continued for another year. On average, the semaglutide group regained about two-thirds of its prior weight loss, while remaining below its original mean weight. Several cardiometabolic measurements moved back toward baseline.

This was an exploratory extension in a subset, rather than the same randomized withdrawal design as STEP 4. Ending lifestyle support alongside medication also affects the question being answered. The results support discussing maintenance as a real part of care, but they cannot isolate every influence on a person’s later course or predict a specific individual’s regain.

What these studies do not decide

Neither finding is a personalized instruction to continue indefinitely, stop abruptly, taper on a particular schedule or combine medicines. They do not establish that everyone regains the same amount. They also do not make a short interruption equivalent to the off-treatment periods studied. Avoid turning a group average into a deadline, a certainty or a self-directed dosing strategy.

A continuity conversation before there is a gap

• Ask what long-term treatment is intended to accomplish and how that goal will be reviewed.
• Identify who handles refill problems, adverse effects and changes in coverage.
• Ask what follow-up would be needed if the medicine were discontinued.
• Discuss how existing nutrition, activity and other clinical support would continue.
• Request product-specific instructions if treatment is interrupted; do not infer a restart dose from an old prescription.

For a cost comparison, include continuity rather than only the introductory month. Record the recurring medicine cost, visits, expected review points and who can be reached when a refill is delayed. A service can be inexpensive initially yet difficult to sustain. That practical uncertainty deserves an explicit discussion before it determines the treatment course by accident.

Keep observations separate from conclusions

If a treatment change occurs, a simple dated record can help the clinical review: when the change happened, which product was used, weight measurements and relevant symptoms or other medication changes. The clinician can decide which monitoring is appropriate. Do not label every later change as a withdrawal effect without considering the broader situation. The studies make a strong case for planning and follow-up, while leaving the individual decision to a clinical assessment.